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high mortality. In Colombia, a high proportion of patients
never received antifungal therapy even with laboratory
proven infection.
doi:10.1016/j.ijid.2010.02.176714th International Congress on Infectious Diseases (ICID) Abs
was remarkable for hypotension and tachycardia (no oral
thrush). Esophagogastroduodenoscopy revealed fecal mat-
ter in the esophagus and stomach. Post volvulus repair, the
patient developed sepsis, secondary to an esophageal perfo-
ration. Surgical closure was performed and she was treated
with broad spectrum antibiotics and corticosteroids. Blood
cultures were positive for Candida albicans (two occasions)
and Saccharomyces cerevisiae (one occasion) fungemia. Flu-
conazole was added to the antibiotic treatment. Patient
never fully recovered and care was withdrawn.
Conclusion: Disseminated Saccharomyces infection has
been reported in immunosuppressed patients treated with
probiotics, but disseminated Saccharomyces cerevisiae
infection associated with underlying esophageal disease is
not previously described. Saccharomyces cerevisiae (which
occasionally colonizes the gastrointestinal tract) is closely
related to Candida albicans, and may be misidentiﬁed by
common automated microbiologic systems. The relative
resistance of Saccharomyces cerevisiae to azole drugs and
its ability to cause widespread infections with multi-organ
involvement makes rapid, correct identiﬁcation critical.
Using the standard yeast card, the Vitex-2 system iden-
tiﬁed one yeast as Saccharomyces cerevisiae and one
as Zygosaccharomyces bailii. We found no documented
cases of Zygosaccharomyces fungemia so we employed DNA
sequencing to conﬁrm the Vitek identiﬁcation. Based on the
nucleotide sequence of the D1/D2 LSU ribosomal RNA gene
both the fungi were identiﬁed as Saccharomyces cerevisiae.
doi:10.1016/j.ijid.2010.02.1765
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promised patients
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Background: The aim of the study was to compare anti-
fungal sensitivity of yeasts to selected antimycotics isolated
from immunocompromised patients with hematooncological
disorders and critically diseased patients in intensive care
units with sensitivity of yeasts isolated from immunocompe-
tent individuals.
Methods: Within the period between August 2007 and
October 2008, we examined 450 samples of clinical mate-
rial isolated from hospitalized patients with both proven
and suspected mycotic infection. Yeasts isolates were iden-
tiﬁed by Chromagar Candida and AUXACOLOR 2 biochemical
test. Susceptibility to antimycotic agents such as ﬂuconazole
(FLZ), ketoconazole (KTZ), itraconazole (ITZ), voricona-
zole (VRZ), ﬂucotysine (5FC), amphotericin B (AMB), and
caspofungin (CAF) was determined by microdilution method
according to CLSI M27-A2 standard procedure.
Results: Among all isolates nine yeast species were iden-
tiﬁed, the most frequently C. albicans strains (n = 151),
followed by C. glabrata (n = 21), C. krusei (n = 11), S. cere-
visiae (n = 8), C. parapsilosis (n = 7), C. tropicalis (n = 3), C.
guiliermondii (n = 3), C. kefyr (n = 2) and C. lusitaniae (n = 2).
Among yeasts isolated from immunocompromised patients
the incidence of non-albicans Candida was 42.6% while
only 17% among yeasts isolated from immunocompetentts e127
atients. Incidence of resistance of commonly susceptible
pecies to the tested antimycotics was rare. The resis-
ance to 5-FC (MIC≥ 32g/mL) was showed only in case
f two C. albicans strains. The highest resistance, specif-
cally to azole antimycotics, was observed in C. glabrata
trains, amongst which, except VRZ (MIC≥ 32g/mL), resis-
ant strains to FLZ (MIC≥ 64g/mL), KTZ (MIC > .125g/mL)
nd ITZ (MIC≥ 1g/mL) were found.
Conclusion: Results obtained in the study showed a higher
ncidence of non-albicans Candida yeasts in immunocompro-
ised patients. We did not ﬁnd signiﬁcant differences in
usceptibility of yeasts isolated from immunocompromised
nd immunocompetent patients.
oi:10.1016/j.ijid.2010.02.1766
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Background: Candidemia is a serious infectious compli-
ation among critical and immunosupressed patients.
Methods: Patients with laboratory conﬁrmed candidemia
ere prospectively followed. Candida isolates were sent to
reference laboratoryfor identiﬁcation and susceptibility.
isk factors and clinical data were taken from the medical
ecord. Antifungal use and ﬁnal outcome were registered.
Results: 131 episodes were followed, 61% women, with
ges between 9 days and 87 years. 50% of blood cultures
ere positive after 34 hours (in 44% of the patients blood
ultures were posiitve in more than one bottle). More fre-
uently found risk factors for candidemia were stay in ICU
8%), previous antibiotic use (77%), parenteral nutrition
54%), previous abdominal surgery (40%), previous use of
mmunosuppresors (29%). Candida species identiﬁes were C.
lbicans (67%), followed by C. parapsilosis (14%) and C. trop-
calis (10%). Susceptibility to ﬂuconazole were high among
. albicans and C. tropicalis isolates, but not for the other
onalbicans isolates. Fluconazole was the preferred drug of
hoice (57%), followed by amphotericin deoxycholate (18%).
8% of the patients never received antifungal therapy. Mor-
ality was high after two weeks of treatment (20%) and was
ven higher at discharge (36%).
Conclusion: Candidemia is a severe complication with
